Therapeutic Aflibercept fusion antibody from the original Eylea® commercial drug

Showing the single result

Filter our product list:
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Expiry Date
Filters Sort results
Reset Apply


Molecular Class
Drug Brand
Product Concentration
Quantity per vial
Storage Temperature
Expiry Date
Fusion protein
40 mg/mL
0,8 mg
view product
Max: 2
Min: 1
Step: 1

Not looking for Aflibercept?

Search our therapeutic molecules product database

Eylea® / Aflibercept Reference Product

Drug nameEylea®
API typeFusion protein consisting of portions of human VEGF (Vascular Endothelial Growth Factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology
Pharmacotherapeutic group
Ophthalmologicals / Antineovascularisation agents
ATC code
Target of antibody
Vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF)
General functionAflibercept is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A). It can also attach to other proteins such as placental growth factor (PlGF). VEGF-A and PlGF are involved in stimulating the abnormal growth of blood vessels in patients with AMD, certain types of macular oedema and myopic choroidal neovascularisation. By blocking these factors, aflibercept reduces the growth of the blood vessels and controls the leakage and swelling.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Wet AMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal thickening or oedema and/or sub-/intra-retinal haemorrhage, resulting in loss of visual acuity. In patients treated with Eylea, central retinal thickness [CRT] decreased soon after treatment initiation, and the mean CNV lesion size was reduced.
Original license holder
Bayer AG
Müllerstraße 178
13353 Berlin
Marketing authorisation numbers
Marketing authorisation holder
Bayer AG
51368 Leverkusen
Name of the manufacturer of the biological active substance
Regeneron Pharmaceuticals, Inc. 81 Columbia Turnpike Rensselaer, New York 12144 USA
Name and address of the manufacturer(s) responsible for batch releaseBayer AG
Müllerstraße 178
13353 Berlin
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Polysorbate 20
Sodium dihydrogen phosphate, monohydrate
Disodium hydrogen phosphate, heptahydrate
Sodium chloride
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.

we are recruiting